Lenalidomide Accord

Lenalidomide, the active ingredient in Lenalidomide Accord, is a Immunomodulatory imide drug (IMiD) presented as a tablet for oral use. It is employed in the treatment of certain blood‑related cancers, primarily multiple myeloma and myelodysplastic syndromes, in adult patients. GNH USA supplies Lenalidomide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders. - Multiple myeloma: improves progression‑free and overall survival when combined with dexamethasone or other agents. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves blood counts. - Mantle cell lymphoma (relapsed/refractory): provides clinical benefit as part of combination therapy.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: lowered neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet count, may cause easy bruising. - Diarrhea: loose stools, sometimes leading to dehydration. - Constipation: difficulty passing stool. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophils requiring medical intervention. - Severe thrombocytopenia: dangerously low platelets with bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Lenalidomide requires careful monitoring and specific safety measures. - Pregnancy contraindication: teratogenic; ensure effective contraception for both patient and partner. - Thrombosis risk: assess need for prophylactic anticoagulation, especially with additional risk factors. - Hematologic monitoring: regular CBCs to detect neutropenia or thrombocytopenia. - Renal impairment: dose adjustment may be needed in patients with reduced kidney function. - Drug interaction vigilance: avoid concurrent use with strong CYP3A4 inhibitors without supervision. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Thalidomide: additive teratogenic and hematologic toxicity. - Anticoagulants (e.g., warfarin): heightened risk of thromboembolic events.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Live vaccines: immunosuppression can diminish vaccine response. - NSAIDs: may increase risk of renal impairment when combined with lenalidomide.